Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Significant Accounting Policies [Abstract]

Schedule of Restrictions on Cash and Cash Equivalents

The cash, cash equivalents, and restricted cash balance included the following (in thousands):

	March 31,		December 31,
	2026		2025
Cash	$	460	$	624
Cash equivalents		52,198		373,063
Restricted cash		132		132
Total cash, cash equivalents, and restricted cash	$	52,790	$	373,819

Schedule of Research and Development Expense

The chief operating decision-maker reviews research and development expenses by the following significant categories presented in the table below (in thousands):

	Three months ended March 31,
	2026		2025
Research and development trials and consumables expenses	$	28,848	$	13,278
Payroll and personnel expenses		9,455		5,561
Facilities and other expenses		1,499		1,796
Total research and development	$	39,802	$	20,635